Bivatuzumab mertansine explained

Bivatuzumab mertansine is a combination of bivatuzumab, a humanized monoclonal antibody, and mertansine, a cytotoxic agent. It is designed for the treatment of squamous cell carcinoma.[1]

Notes and References

  1. Tijink BM, Buter J, de Bree R, Giaccone G, Lang MS, Staab A, Leemans CR, van Dongen GA . 6 . A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus . Clinical Cancer Research . 12 . 20 Pt 1 . 6064–72 . October 2006 . 17062682 . 10.1158/1078-0432.CCR-06-0910 . free .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Bivatuzumab mertansine".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.